Bempedoic acid: for whom and when
Abstract Purpose of Review The aim of creating an orally active non-statin cholesterol-
lowering drug was achieved with bempedoic acid, a small linear molecule providing both a …
lowering drug was achieved with bempedoic acid, a small linear molecule providing both a …
[HTML][HTML] Bempedoic acid in the management of lipid disorders and cardiovascular risk. 2023 position paper of the International Lipid Expert Panel (ILEP)
Cardiovascular disease (CVD) is a chronic non-communicable disease (NCD) and the
predominant cause of morbidity and mortality worldwide. Substantial reductions in the CVD …
predominant cause of morbidity and mortality worldwide. Substantial reductions in the CVD …
[HTML][HTML] Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials
Background Statin therapy is effective for the prevention of atherosclerotic cardiovascular
disease and is widely prescribed, but there are persisting concerns that statin therapy might …
disease and is widely prescribed, but there are persisting concerns that statin therapy might …
[HTML][HTML] Red yeast rice for dyslipidaemias and cardiovascular risk reduction: A position paper of the International Lipid Expert Panel
The risk of atherosclerotic cardiovascular disease (ASCVD) is strongly related to lifetime
exposure to low-density lipoprotein (LDL)-cholesterol in longitudinal studies. Lipid-lowering …
exposure to low-density lipoprotein (LDL)-cholesterol in longitudinal studies. Lipid-lowering …
[HTML][HTML] 2023: The year in cardiovascular disease–the year of new and prospective lipid lowering therapies. Can we render dyslipidemia a rare disease by 2024?
In 2023 there are still even 75% of patients over the target of low-density lipoprotein
cholesterol (LDL-C), and hypercholesterolemia is the most common and the worst monitored …
cholesterol (LDL-C), and hypercholesterolemia is the most common and the worst monitored …
[HTML][HTML] A look to the past–what has had the biggest impact on lipids in the last four decades? A personal perspective
We live in interesting times, when we finally have the possibility of effective treatment of
patients with lipid disorders, and in fact with numerous effective drugs available, it should be …
patients with lipid disorders, and in fact with numerous effective drugs available, it should be …
Anti-fibrotic effects of statin drugs: A review of evidence and mechanisms
Fibrosis is a pathological repair process common among organs, that responds to damage
by replacement of tissue with non-functional connective tissue. Despite the widespread …
by replacement of tissue with non-functional connective tissue. Despite the widespread …
[HTML][HTML] 2022: the year in cardiovascular disease–the year of upfront lipid lowering combination therapy
Recent data clearly show that we are extremely ineffective in the use of lipid-lowering
therapy (LLT). Furthermore, the problem seems to be the most serious in the group of …
therapy (LLT). Furthermore, the problem seems to be the most serious in the group of …
Management of statin intolerant patients in the era of novel lipid lowering therapies: A critical approach in clinical practice
G Bosco, F Di Giacomo Barbagallo… - Journal of Clinical …, 2023 - mdpi.com
Statins are the cornerstone of lipid-lowering therapies effective for cardiovascular risk
reduction. Although they are generally well tolerated, statin intolerance (SI) is frequent in …
reduction. Although they are generally well tolerated, statin intolerance (SI) is frequent in …
Statin intolerance: time to stop letting it get in the way of treating patients
M Banach - The Lancet, 2022 - thelancet.com
Statins, more than any other drugs in the 21st century, have completely changed the ability
to prevent cardiovascular disease events and to prolong the lives of patients. 1 However, the …
to prevent cardiovascular disease events and to prolong the lives of patients. 1 However, the …